NCT04811131

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Arcutis Biotherapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.

Detailed description

This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo. This study was prematurely terminated by the sponsor on 30-Jun-2021.

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	ARQ-252 cream 0.3%	ARQ-252 cream 0.3%
DRUG	ARQ-252 Vehicle cream	ARQ-252 Vehicle cream
DEVICE	NB-UVB phototherapy active treatment	NB-UVB phototherapy active treatment
DEVICE	NB-UVB phototherapy sham treatment	NB-UVB phototherapy sham treatment

Timeline

• Start date: 2021-03-04
• Primary completion: 2021-08-09
• Completion: 2021-08-09
• First posted: 2021-03-23
• Last updated: 2024-07-12
• Results posted: 2024-07-12

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study